RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE- B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer re ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will. ...

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas†) today announced positive results from the Phase 3 EV- 304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative. ...

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares are down early Friday following the company’s strong fourth-quarter report.ANI Pharmaceuticals reported adjusted earnings of $2.33 per share, up from $1.63 a year ago, beating the consensus of $2.00.Total net revenues for the fourth quarter reached $247.1 million, marking a 29.6% increase compared to the same period last year. The sales surpassed the consensus estimate of $231.53 million.The Rare Disease segment, which includes products like Cortrophin Gel, saw ...

Key Takeaways Novavax reported Q4 EPS of 11 cents, beating loss estimates as revenues rose 67% year over year.NVAX posted $108M in licensing revenues, including $98M under its Sanofi agreement.Novavax expects 2026 adjusted revenues of $230M-$270M, excluding Sanofi receivables.Novavax (NVAX) reported earnings of 11 cents per share in the fourth quarter of 2025 against the Zacks Consensus Estimate of a loss of 66 cents. In the year-ago quarter, the company had recorded a loss of 51 cents.Quarterly revenues to ...

ANI Pharmaceuticals (NasdaqGM:ANIP) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChristopher Mutz - SVP and Head of Rare DiseaseCourtney Mogerley - Managing DirectorGlen Santangelo - Managing DirectorLeszek Sulewski - VP of Spec Pharma and Biotech Equity ResearchNikhil Lalwani - President and CEOStephen Carey - SVP and CFOVamil Divan - Managing DirectorConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystThomas ...

ANI Pharmaceuticals (NasdaqGM:ANIP) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChristopher Mutz - SVP and Head of Rare DiseaseCourtney Mogerley - Managing DirectorGlen Santangelo - Managing DirectorLeszek Sulewski - VP of Spec Pharma and Biotech Equity ResearchNikhil Lalwani - President and CEOStephen Carey - SVP and CFOVamil Divan - Managing DirectorConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystThomas ...

ANI Pharmaceuticals (NasdaqGM:ANIP) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Speaker8Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meetin ...

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”). Each subscription right now entitles holders to purchase one unit (th ...